We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
26
Cartesian Therapeutics
RNAC
$225M
$6.55M 1.14%
+242,370
New +$5.78M
SLRN
27
DELISTED
ACELYRIN
SLRN
$6.51M 1.13%
1,475,074
-89,266
-6% -$418K
CORT icon
28
CALL
Corcept Therapeutics
CORT
$10.1B
$6.04M 1.05%
1,860
-277,640
-99% -$7.61M
NBIX icon
29
Neurocrine Biosciences
NBIX
$18.4B
$5.51M 0.96%
+40,000
New +$5.49M
PYXS icon
30
Pyxis Oncology
PYXS
$184M
$5.5M 0.96%
1,662,408
– –
INSM icon
31
PUT
Insmed
INSM
$22.6B
$4.75M 0.83%
709
-70,191
-99% -$2.72M
ARQT icon
32
Arcutis Biotherapeutics
ARQT
$3.55B
$4.55M 0.79%
489,642
-100,000
-17% -$904K
RCKT icon
33
Rocket Pharmaceuticals
RCKT
$343M
$4.24M 0.74%
197,096
-100,000
-34% -$2.3M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.28B
$4.18M 0.73%
107,187
– –
CRVO icon
35
CervoMed
CRVO
$23.7M
$4.06M 0.71%
237,345
– –
RZLT icon
36
Rezolute
RZLT
$474M
$3.89M 0.68%
+903,744
New +$3.11M
HELP
37
Cybin Inc
HELP
$471M
$3.78M 0.66%
367,197
– –
VRDN icon
38
PUT
Viridian Therapeutics
VRDN
$2.15B
$3.63M 0.63%
2,789
-176,111
-98% -$2.44M
LENZ
39
LENZ Therapeutics
LENZ
$184M
$3.54M 0.62%
204,513
+119,513
+141% +$2.09M
SLN
40
Silence Therapeutics
SLN
$546M
$3.29M 0.57%
+506,665
New +$10.8M
INBX icon
41
Inhibrx
INBX
$1.17B
$3.26M 0.57%
+230,000
New +$3.59M
ABEO icon
42
Abeona Therapeutics
ABEO
$343M
$3.26M 0.57%
768,593
-120,000
-14% -$612K
INSM icon
43
Insmed
INSM
$22.6B
$3.2M 0.56%
47,835
-3,500
-7% -$136K
ANVS icon
44
PUT
Annovis Bio
ANVS
$71.9M
$3.18M 0.55%
5,517
-246,383
-98% -$2M
TERN
45
DELISTED
Terns Pharmaceuticals
TERN
$3.12M 0.54%
458,497
+370,000
+418% +$2.24M
GTHX
46
PUT
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.93M 0.51%
+12,864
New +$49.1K
VRNA
47
DELISTED
Verona Pharma
VRNA
$2.91M 0.51%
201,116
-174,194
-46% -$2.54M
WVE icon
48
Wave Life Sciences
WVE
$1.13B
$2.87M 0.5%
575,088
-15,000
-3% -$85.6K
GTHX
49
CALL
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.79M 0.49%
+12,248
New +$46.8K
IMVT icon
50
CALL
Immunovant
IMVT
$7.99B
$2.64M 0.46%
+1,000
New +$28.4K
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.